Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068831 · ClinicalTrials.gov registry record · Phase 2
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
A Phase 2 study of Metastatic Renal Cell Carcinoma and Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 7
- Study locations
NCT04068831 is a Phase 2 study of Metastatic Renal Cell Carcinoma and Succinate Dehydrogenase-Deficient Renal Cell Carcinoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants, below the 143-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT04068831, a Phase 2 study of Metastatic Renal Cell Carcinoma and Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
Conditions Studied
Interventions
- DRUG Talazoparib
- DRUG Avelumab
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2023-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04068831
The ClinicalTrials.gov registry entry for NCT04068831 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 37 other Metastatic Renal Cell Carcinoma trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Talazoparib is the first listed.
NCT04068831 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04068831 about?
NCT04068831 is a clinical study titled "Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma". The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.
What is the current status of trial NCT04068831?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2019-08-22. Estimated completion is 2023-12-06.
What conditions does trial NCT04068831 study?
This clinical trial studies the following conditions: Metastatic Renal Cell Carcinoma, Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma.
What interventions are being tested in trial NCT04068831?
The interventions under investigation include: Talazoparib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT04068831?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04068831 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
RECRUITING · Phase 2
-
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RECRUITING · Phase 2
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
RECRUITING · Phase 2
-
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Renal Cell Carcinoma
All registered trials for this condition
Succinate Dehydrogenase-Deficient Renal Cell Carcinoma
All registered trials for this condition
New Jersey
All trials with a study site in New Jersey
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.